Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus
Ben-Gary Harvey, … , Steven Shak, Ronald G. Crystal
Ben-Gary Harvey, … , Steven Shak, Ronald G. Crystal
Published November 1, 1999
Citation Information: J Clin Invest. 1999;104(9):1245-1255. https://doi.org/10.1172/JCI7935.
View: Text | PDF
Article

Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus

  • Text
  • PDF
Abstract

We sought to evaluate the ability of an E1–, E3– adenovirus (Ad) vector (AdGVCFTR.10) to transfer the normal human cystic fibrosis transmembrane conductance regulator (CFTR) cDNA to the airway epithelium of individuals with cystic fibrosis (CF). We administered AdGVCFTR.10 at doses of 3 × 106 to 2 × 109 plaque-forming units over 9 months by endobronchial spray to 7 pairs of individuals with CF. Each 3-month cycle, we measured vector-derived versus endogenous CFTR mRNA in airway epithelial cells prior to therapy, as well as 3 and 30 days after therapy. The data demonstrate that (a) this strategy appears to be safe; (b) after the first administration, vector-derived CFTR cDNA expression in the CF airway epithelium is dose-dependent, with greater than 5% endogenous CFTR mRNA levels at the higher vector doses; (c) expression is transient, lasting less than 30 days; (d) expression can be achieved with a second administration, but only at intermediate doses, and no expression is observed with the third administration; and (e) the progressive lack of expression with repetitive administration does not closely correlate with induction of systemic anti-Ad neutralizing antibodies. The major advantage of an Ad vector is that it can deliver sufficient levels of CFTR cDNA to the airway epithelium so that CFTR expression protects the lungs from the respiratory manifestations of CF. However, this impressive level of expression is linked to the challenging fact that expression is limited in time. Although this can be initially overcome by repetitive administration, unknown mechanisms eventually limit this strategy, and further repetitive administration does not lead to repetitive expression.

Authors

Ben-Gary Harvey, Philip L. Leopold, Neil R. Hackett, Tina M. Grasso, P. Mickey Williams, Ayly L. Tucker, Robert J. Kaner, Barbara Ferris, Igor Gonda, Theresa D. Sweeney, Ramachandran Ramalingam, Imre Kovesdi, Steven Shak, Ronald G. Crystal

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Quantitative assessment of the airway epithelium for the percentage of e...
Quantitative assessment of the airway epithelium for the percentage of exogenous CFTR mRNA compared with endogenous CFTR mRNA as a function of dose and time (baseline, days 3 and 30) after endobronchial spray of the third dose (cycle 3) of the vector. The dashed line represents the 5% level of exogenous vector-derived CFTR mRNA. Each symbol represents a different individual (see Table 1). (a) Function of dose at day 3. (b) Function of time. “Pre” is day 180 of the study. The data for the 106 and 106.5 doses (undetectable at each time point for all subjects) are not shown in b.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts